Akari Therapeutics (AKTX) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Quoin Pharmaceuticals (QNRX) has outperformed Akari Therapeutics (AKTX) over the past year, losing 44.4% versus a loss of 80.1%. Over five years, AKTX leads with a -99.4% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($21.9 million vs $18.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | QNRX |
|---|---|---|
| Share price | $8.13 | $4.55 |
| Market cap | $18.58M | $21.86M |
| 1-day change | -5.74% | -3.19% |
| YTD return | -29.67% | -68.47% |
| 1-year return | -80.07% | -44.44% |
| 5-year return | -99.38% | -99.99% |
| EPS (TTM) | $0.00 | $-5.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $41.80 |
| 52-week low | $3.02 | $3.25 |
| Distance from 52-week high | -79.67% | -89.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +213.65% | +379.78% |
| Average volume | 61.08K | 541.11K |
| Shares outstanding | 2.29M | 4.80M |
| Employees | 5 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QNRX has outperformed AKTX by 35.6 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Healthcare · Biotechnology · 5 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Healthcare · Biotechnology · 4 employees
AKTX vs QNRX FAQ
Which is bigger, Akari Therapeutics or Quoin Pharmaceuticals?
Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $21.86M compared with $18.58M for Akari Therapeutics (AKTX).
Which stock has performed better over the past year, AKTX or QNRX?
QNRX returned -44.44% over the past 12 months, compared with -80.07% for AKTX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.